publication date: Jun. 7, 2019

NCI Trials

NCI Trials for June

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase I – 10239

A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-Cell Malignancies

NCI Center for Cancer Research

Miljkovic, Milos

(301) 250-5216


Phase I/II – 10183

A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma

Northwestern University EDDOP

Hussain, Maha H. A.

(312) 908-5487


Phase II – 10247

A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Comprehensive Cancer Center LAO

Jonas, Brian Andrew

(916) 734-3772


Phase II – EAQ172

Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

ECOG-ACRIN Cancer Research Group

Naidoo, Jarushka

(410) 550-2646


Phase II – EAZ171

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women

ECOG-ACRIN Cancer Research Group

Schneider, Bryan Paul

(317) 274-6473


Phase II – NRG-GU007

Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)

NRG Oncology

Michaelson, M. Dror

(617) 726-1594


Phase II – S1800A

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.